Health Care & Life Sciences » Biotechnology | Portola Pharmaceuticals Inc.

Portola Pharmaceuticals Inc.

Portola Pharmaceuticals Inc.
Stock Exchange Frankfurt Stock Exchange
EPS
-
Market Cap
-
Shares Outstanding
66.09 M
Public Float
56.59 M
Portola Pharmaceuticals Inc.
Stock Exchange NASDAQ Stock Market
EPS
$5.18
Market Cap
$1.8 B
Shares Outstanding
68.11 M
Public Float
63.71 M

Profile

Address
270 East Grand Avenue
South San Francisco California 94080
United States
Employees -
Website http://www.portola.com
Updated 07/08/2019
Portola Pharmaceuticals, Inc. engages in the development and commercialization of novel therapeutics in the areas of thrombosis and hematologic disorders, and inflammation. Its FDA-approved medicines include Bevyxxa (betrixaban), the oral, once-daily Factor Xa inhibitor, and Andexxa coagulation factor Xa (recombinant), inactivated-zhzo, the antidote for the Factor Xa inhibitors rivaroxaban and apixaban. The company was founded by Charles J.

Financials

View All

Hollings Chase Renton
Chairman
David C. Stump
Independent Director